EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Dipti Talaulikar iD, Douglas Joshua, Phoebe Joy Ho, John Gibson, Hang Quach, Simon Gibbs iD, Silvia Ling, Christopher Ward, Bradley M Augustson, Judith Trotman iD, Simon J Harrison, Constantine S Tam und 1 weitere

Internal Medicine Journal · 2023

DOI: 10.1111/imj.15980 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2023. Verfasst von Dipti Talaulikar und 12 weiteren Autor:innen. Beteiligte Einrichtung: ACT Pathology, Canberra Hospital, Canberra, Australian Capital Territory, Australia. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Multiple Myeloma, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Waldenström macroglobulinaemia (WM) is an indolent B‐cell malignancy characterised by the presence of IgM paraprotein, bone marrow infiltration by clonal small B lymphocytes with plasmacytic differentiation and the MYD88 L265P mutation in >90% of cases. Traditionally, WM has been treated with chemoimmunotherapy. Recent trials have demonstrated the efficacy and safety of Bruton tyrosine kinase inhibitors in WM, both as monotherapy and in combination with other drugs. There is emerging evidence on the use of other agents including B‐cell lymphoma 2 inhibitors and on the treatment of rare presentations of WM. In this update, the Medical and Scientific Advisory Group of Myeloma Australia reviews the available evidence on the treatment of WM since the last publication in 2017 and provides specific recommendations to assist Australian clinicians in the management of this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaMultiple MyelomaAntineoplastic AgentsHumansAustraliaBone MarrowMutationMyeloid Differentiation Factor 88

Stichwörter der Autor:innen

Bruton tyrosine kinase inhibitorWaldenström macroglobulinaemiatreatment

Substanzen

Antineoplastic AgentsMyeloid Differentiation Factor 88

Autor:innen und Institutionen

  • ACT Pathology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
  • College of Health and Medicine, Australian National University, Australian Capital Territory, Canberra, Australia.
  • Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • University of Sydney, Sydney, New South Wales, Australia.
  • St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.

ORCID-Profile: Dipti Talaulikar, Simon Gibbs, Judith Trotman

Zitieren

APA

Talaulikar, D., Joshua, D., Ho, P. J., Gibson, J., Quach, H., Gibbs, S., Ling, S., Ward, C., Augustson, B. M., Trotman, J., Harrison, S. J., Tam, C. S., & Medical and Scientific Advisory Group, Myeloma Australia (2023). Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal. https://doi.org/10.1111/imj.15980

Vancouver

Talaulikar D, Joshua D, Ho PJ, Gibson J, Quach H, Gibbs S, et al. Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal. 2023. doi:10.1111/imj.15980

BibTeX
@article{Talaulikar2023,
  author = {Talaulikar, Dipti and Joshua, Douglas and Ho, Phoebe Joy and Gibson, John and Quach, Hang and Gibbs, Simon and Ling, Silvia and Ward, Christopher and Augustson, Bradley M and Trotman, Judith and Harrison, Simon J and Tam, Constantine S and Medical and Scientific Advisory Group, Myeloma Australia, Medical and Scientific Advisory Group, Myeloma Australia},
  title = {Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group},
  journal = {Internal Medicine Journal},
  year = {2023},
  doi = {10.1111/imj.15980}
}
Kostenlos starten →